EMERGENT BIOSOLUTIONS INC (EBS)

US29089Q1058 - Common Stock

1.944  +0.04 (+2.32%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
1.774B
14.03%		1.118B
-36.99%		1.049B
-6.10%		1.035B
-1.36%
EBITDA
YoY % growth
506.9M
-14.75%		-20M
-103.95%		-76.4M
-282.00%		75.75M
199.15%		N/AN/A
EBIT
YoY % growth
383.1M
-20.20%		-163.3M
-142.63%		-201.5M
-23.39%		1.01M
100.50%		N/AN/A
Operating Margin
21.60%-14.61%-19.20%0.10%N/AN/A
EPS
YoY % growth
6.00
-23.57%		-2.26
-137.67%		-5.48
-142.48%		-2.02
63.14%		N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.84
73.56%
Revenue
Q2Q % growth		226.75M
37.34%
EBITDA
Q2Q % growth		-5.555M
EBIT
Q2Q % growth		-40.905M
72.38%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.77
-148.39%		-0.19-0.58-301.25%
Q3 2023
Q2Q % growth		 -0.48
62.20%		-0.23-0.25-112.80%
Q2 2023
Q2Q % growth		 -1.06
-23.26%		-0.49-0.57-115.65%
Q1 2023
Q2Q % growth		 -3.17
-1,861.11%		-1.25-1.92-153.11%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 276.6M
-16.36%		296.47M-19.87M-6.70%
Q3 2023
Q2Q % growth		 270.5M
12.71%		239.81M30.69M12.80%
Q2 2023
Q2Q % growth		 502.2M
106.92%		218.33M283.87M130.02%
Q1 2023
Q2Q % growth		 165.1M
-46.31%		144.71M20.39M14.09%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-33.87% -223.37% -229.87% -311.27%
Revenue0% 19.32% -13.46% -3.81%